Hebei Medical University Fourth Hospital
166
51
56
17
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
3.0%
5 terminated/withdrawn out of 166 trials
77.3%
-9.3% vs industry average
14%
23 trials in Phase 3/4
6%
1 of 17 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (166)
Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)
Role: lead
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC
Role: lead
PregnAncy-Related Aortic DISsEction in China
Role: collaborator
Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
Role: lead
Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases
Role: collaborator
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
Role: lead
Sedation in ICU Patients With Mechanical Ventilation
Role: collaborator
SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma
Role: lead
Cardiac Safety Management and Immune Microenvironment Changes After Thoracic Radiotherapy: A Prospective Observational Study
Role: lead
Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy
Role: collaborator
Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
Role: lead
A Clinical Study of SHR-1701 Combined With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Siewert Type II Adenocarcinoma of the Esophagogastric Junction
Role: lead
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
Role: collaborator
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
Role: collaborator
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
Role: lead
Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation
Role: collaborator
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
Role: collaborator
A Real-World Study on the Impact of Different Adjuvant Treatment Regimens on Prognosis in Non-pCR Patients With HER2-Positive Breast Cancer After Neoadjuvant Therapy
Role: lead
Laparoscopic Staging for Stage III Gastric Cancer
Role: collaborator
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
Role: lead